Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
<p><strong>Objective:</strong> PCSK9 inhibitors have been shown to reduce LDLc by up to about 60% and 85% when used with high doses of statins and ezetimibe (2019 ESC/EAS Guidelines). These therapies may lead to very low levels of LDLc and have been associated with possible cogn...
Main Authors: | José Seijas-Amigo, Diego Rodríguez-Penas, Ana Estany-Gestal, Pedro Suárez-Artime, María Santamaría-Cadavid, José Ramón González-Juanatey |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2021-05-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/11569.pdf |
Similar Items
-
What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
by: Remo H. M. Furtado, et al.
Published: (2020-02-01) -
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01) -
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01) -
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01) -
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)